Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Sep 28; 404(10459):1240-1252.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Chemotherapy, Adjuvant
Cisplatin
Double-Blind Method
Female
Humans
Lung Neoplasms
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Quality of Life

authors with profiles

Marina Chiara Garassino